Compare KEQU & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | NRXP |
|---|---|---|
| Founded | 1906 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.9M | 99.2M |
| IPO Year | 1995 | N/A |
| Metric | KEQU | NRXP |
|---|---|---|
| Price | $36.02 | $3.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 1.3K | ★ 1.7M |
| Earning Date | 03-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.09 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | $17.49 | ★ N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $33.70 | $1.65 |
| 52 Week High | $60.89 | $5.06 |
| Indicator | KEQU | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 43.59 | 55.17 |
| Support Level | $37.04 | $1.89 |
| Resistance Level | $41.25 | $5.06 |
| Average True Range (ATR) | 0.69 | 0.46 |
| MACD | -0.46 | -0.02 |
| Stochastic Oscillator | 15.96 | 48.06 |
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.